Menu

Source Legend
  • Human-provided

    Entered or confirmed by an authorized person.

  • Google

    Imported Google information.

  • Trial-derived

    Calculated or extracted directly from associated trial records.

  • AI-inferred

    A capability inferred from trial history.

  • AI-extracted

    An explicit statement extracted from an official source.

  • Public registry

    Information from a public registry.

  • Site record

    Information held in the site record.

Source: Site record. Hospital Garcia de Orta

Claim This Site

Are you the site administrator? Claim this site to update information.

Basic Information

Site Overview

Source: Human-provided.

Garcia de Orta Hospital (HGO) is a public-law corporate entity with administrative, financial, and asset-management autonomy.HGO currently serves an estimated population of approximately 350,000 residents in the municipalities of Almada and Seixal. For certain services, its catchment area extends well beyond these two municipalities to cover the entire Setúbal Peninsula, particularly in specialties such as neonatology and neurosurgery.HGO has a capacity of 545 beds distributed across various specialties and referral services that regularly provide support to other hospitals. The hospital currently employs approximately 2,500 people.

Business Status

Source: Google. OPEN

Business Category

Source: Google. General hospital

Business Subcategory

Source: Google. General hospital
Source: Google. Hospital
Source: Trial-derived.
35Total Trials
Source: Trial-derived.
2Recruiting Trials
Source: Trial-derived.
11Active Trials
Source: Trial-derived.
19Completed Trials
Source: Trial-derived.
50Unique Conditions
Source: Trial-derived.
31Unique Sponsors

Conditions

Source: Trial-derived. Diabetes Mellitus, Type 2 (4)Source: Trial-derived. Breast Cancer (2)Source: Trial-derived. Chronic Kidney Disease (2)Source: Trial-derived. Metastatic Colorectal Cancer (2)Source: Trial-derived. Acute Coronary Syndrome (1)Source: Trial-derived. Acute Myocardial Infarction (1)Source: Trial-derived. Acute Non-cardioembolic Ischemic Stroke (1)Source: Trial-derived. Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (1)

Sponsors

Source: Trial-derived. Bayer (4)Source: Trial-derived. Hoffmann-La Roche (4)Source: Trial-derived. Novo Nordisk A/S (4)Source: Trial-derived. ADIR, a Servier Group company (2)Source: Trial-derived. Amgen (2)Source: Trial-derived. Boehringer Ingelheim (2)Source: Trial-derived. Hospital Garcia de Orta (2)Source: Trial-derived. Institut de Recherches Internationales Servier (2)

Facilities & Operations

Facilities and operational capabilities inferred from trial participation

Source: AI-inferred. Overnight or inpatient research stays supported

Research Technology

Research technology inferred from trial participation

Source: AI-inferred. Telehealth study visits
Source: AI-inferred. Electronic data capture

Imaging & Diagnostics

Imaging and diagnostic capabilities inferred from trial participation

Source: AI-inferred. Electrocardiography (lead count not stated)
Source: AI-inferred. MRI
Source: AI-inferred. 12-lead ECG
Source: AI-inferred. Continuous glucose monitoring
Source: AI-inferred. ETDRS 4 m visual-acuity lane
Source: AI-inferred. Echocardiography
Source: AI-inferred. Fundus photography
Source: AI-inferred. Six-minute walk test

Laboratory & Biospecimens

Laboratory and biospecimen capabilities inferred from trial participation

Source: AI-inferred. Clinical laboratory testing
Source: AI-inferred. Timed pharmacokinetic sampling and processing
Source: AI-inferred. PCR / molecular
Source: AI-inferred. Specimen packaging and shipment
Source: AI-inferred. Immunogenicity (anti-drug antibody) testing
Source: AI-inferred. Pharmacokinetic bioanalysis

Research Pharmacy & Investigational Product

Investigational-product capabilities inferred from trial participation

Source: AI-inferred. Hazardous / cytotoxic drug handling

Clinical Procedures

Clinical procedures inferred from trial participation

Source: AI-inferred. Intravenous infusion administration
Source: AI-inferred. Cardiac catheterisation or electrophysiology procedures
Source: AI-inferred. Liver biopsy

Accessibility & Parking

Accessibility Features

Source: Google. Wheelchair accessible entrance
Source: Google. Wheelchair accessible parking lot
Source: Google. Wheelchair accessible restroom

Additional Capabilities

Other capabilities inferred from trial participation

Source: AI-inferred. Home study visit (provider not specified)
Source: AI-inferred. Intracoronary pressure-wire physiology (FFR)
Source: AI-inferred. Nebulised study drug administration
Source: AI-inferred. Nine-hole peg testing
Source: AI-inferred. Supplemental oxygen therapy
Source: AI-inferred. Timed 25-foot walk testing
Source: AI-inferred. Tumour BRAF V600 mutation testing